Related Experiment Videos
High-affinity 3H-imipramine binding: a new biological marker in depression
Pharmacopsychiatria
|January 1, 1982
Summary
Tricyclic antidepressants bind to specific sites in the brain and platelets. Lower binding site density in platelets may indicate depression, suggesting a potential biological marker for affective disorders.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- High-affinity binding sites for 3H-imipramine, a tricyclic antidepressant, are present in the brain.
- These binding sites are linked to the serotonin neuronal uptake mechanism.
- Similar binding sites are found in human and animal blood platelets.
Purpose of the Study:
- To investigate the role of 3H-imipramine binding sites as a potential biological marker for depression.
- To explore the relationship between antidepressant therapies and the density of these binding sites.
Main Methods:
- Demonstration of high-affinity 3H-imipramine binding in brain tissue.
- Identification of identical binding sites in blood platelets.
- Clinical studies comparing binding site density in depressed patients and healthy volunteers.
- Longitudinal studies during antidepressant treatment and recovery.
Main Results:
- Chronic antidepressant treatment or therapies like electroshock and sleep deprivation decrease brain 3H-imipramine binding site density.
- Untreated depressed patients exhibit lower platelet 3H-imipramine binding site density compared to controls.
- Platelet binding site density remains relatively stable during antidepressant treatment and recovery.
Conclusions:
- 3H-imipramine binding sites in platelets represent a potential biological marker for depression.
- These binding sites can serve as a valuable research tool in the study of affective disorders and psychopharmacology.